Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 10/20 | 0.61 |
| ▸ | CA9 | Q16790 | 6/20 | 0.59 |
| ▸ | CA12 | O43570 | 4/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3359458 | 0.97 | CA2 (0.72) | CA2KDM4EKMT2ACA1CA9 | |
| SCHEMBL3352783 | 0.95 | CA2 (0.72) | CA2KDM4EKMT2ACA1CA9 | |
| SCHEMBL3357517 | 0.95 | CA2 (0.71) | CA2KDM4EKMT2ACA1CA9 | |
| SCHEMBL3324697 | 0.95 | CA2 (0.71) | CA2KDM4EKMT2ACA1CA9 | |
| SCHEMBL3355307 | 0.92 | CA2 (0.68) | CA2KDM4EKMT2ACA1CA9 | |
| SCHEMBL3324262 | 0.91 | CA2 (0.69) | CA2KDM4EKMT2ACA1CA9 | |
| SCHEMBL3355609 | 0.90 | CA2 (0.68) | CA2KDM4EKMT2ACA1CA9 | |
| SCHEMBL3326602 | 0.90 | CA2 (0.68) | CA2KDM4EKMT2ACA1CA9 | |
| SCHEMBL3323540 | 0.86 | KDM4E (0.74) | CA2KDM4EKMT2ACA1CA9 | |
| SCHEMBL15906767 | 0.86 | CA2 (1.00) | CA2KDM4EKMT2ACA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142499-B1 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma | UNIMED PHARMA SPOL SRO (SK) | 2014-12-10 | — | — | EP | claimed |
| US-8193184-B2 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use | Unimed Pharma, SPOL, S.R.O. (SK) | 2012-06-05 | — | — | US | claimed |
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2010-05-20 | — | — | US | claimed |
| EP-2142499-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | Unimed Pharma, Spol. S R.O. (SK) | 2010-01-13 | — | — | EP | claimed |
| WO-2008130332-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2008-10-30 | — | — | WO | claimed |
| EP-2142499-B1 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma | UNIMED PHARMA SPOL SRO (SK) | 2014-12-10 | — | — | EP | disclosed |
| US-8193184-B2 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use | Unimed Pharma, SPOL, S.R.O. (SK) | 2012-06-05 | — | — | US | disclosed |
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2010-05-20 | — | — | US | disclosed |
| EP-2142499-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | Unimed Pharma, Spol. S R.O. (SK) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008130332-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | ARSA, SMS, SULT1E1 | CA2 36/4885KDM4E 438/4885KMT2A 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.